PRF Technologies Ltd.
PRFX · XNASCIK 1801834fmd_1NM3RGFBAYJ77G465X0G52M47YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 15 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 0 |
| Net interest income | – | – | (1) | 0 | 0 | – | – | – |
| Cost of revenue | – | – | – | – | – | 0 | 0 | 0 |
| Gross profit | – | – | – | – | – | 0 | 0 | (0) |
| Research and development | 0 | 0 | 0 | 3 | 4 | 6 | 12 | 1 |
| Selling, general and administrative | – | – | – | 2 | 2 | 2 | 1 | 1 |
| Operating income | (1) | (1) | (2) | (7) | (9) | (10) | (15) | (5) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (1) | (1) | (0) | 0 | 0 | 0 | 0 |
| Income before taxes | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (1) | (4) | (7) | (9) | (9) | (15) | (5) |
| Net income | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) |
| Net income to common shareholders | (2) | (2) | (4) | (7) | – | – | – | – |